We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement
Analytical Cannabis Logo
×
Home > News > Policy > Content Piece

FDA Issues Warning Letters to Five CBD Companies

By Leo Bear-McGuinness

Published: Nov 23, 2022   

Complete the form below and we will email you a PDF version of "FDA Issues Warning Letters to Five CBD Companies"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Analytical Cannabis?

Analytical Cannabis Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The US Food and Drug Administration (FDA) has issued warning letters to five companies for selling CBD-infused products.

According to the administration, the products were marketed in a way that may have led consumers to purchase the items without realizing they contained CBD. Some of the gummy and cookie products were also deemed too appealing to children.

Several of the companies were further accused of “illegally selling unapproved CBD products that claim to cure, mitigate, treat or prevent various diseases”.

The companies are:

The companies have 15 working days to explain in writing how they will “address these violations and prevent their recurrence”. Failure to comply could result in legal action, including product seizures.

In its notice, published on November 21, the FDA says that CBD “raises safety concerns, especially with long-term use.”

“The FDA has not found adequate information showing how much CBD can be consumed, and for how long, before causing harm. This is particularly true for vulnerable populations like children and those who are pregnant. People should be aware of the potential risks associated with the use of CBD products.”

 

Like what you just read? You can find similar content on the topic tags shown below.

Policy Science & Health

Stay connected with the latest news in cannabis extraction, science and testing

Get the latest news with the FREE weekly Analytical Cannabis newsletter

 
Advertisement